The case for CGM
The evidence is in. Access hasn't caught up.
We've split the case into four short reads, so you can find what you need without scrolling through everything else.
adults living with diabetes worldwide
of diabetes spending goes to complications
European countries cover T2D on insulin
asks — insulin users, and everyone else
Start here
Four ways in.
Basics
What CGM is, who it's for, and the burden it addresses.
Read →02Evidence
Outcomes, trials, cost-effectiveness — and what we refuse to claim.
Read →03Access
Who can actually get a sensor, and what the guidelines say.
Read →04Spotlights
Denmark, Sweden, Malta, and the countries moving right now.
Read →Our ask
Two lines. That's the whole policy.
01 — Insulin users
Continuous CGM, fully reimbursed, for everyone dependent on insulin — no gate on diabetes type, age or HbA1c.
02 — Everyone else
A reimbursed 2–4 week CGM window each year for people with diabetes not on insulin, with clinical follow-up.